中国胸心血管外科临床杂志

中国胸心血管外科临床杂志

外泌体在非小细胞肺癌早期诊疗中的研究进展

查看全文

肺癌是目前全球范围内最常见的恶性肿瘤之一,同时也是发病率最高、死亡率最高、增长速度最快且预后最差的恶性肿瘤之一。因此为了建立新的诊断和治疗方法,迫切地需要对该病有更深层次的了解。外泌体是细胞分泌的细胞外囊泡的一种,它能够传递各种各样的生物活性分子,如蛋白质、mRNA、mircoRNA、脂质等,其在肺癌的诊断,治疗及预后中的潜在价值已得到大量文献的支持。本文结合国内外最新报道,对外泌体在非小细胞肺癌发生发展、早期诊断、治疗及预后方面进行综述。

Lung cancer is one of the most common malignant tumors in the world, and also one of the most common malignant tumors with the highest incidence, highest mortality, the fastest growth rate and the worst prognosis. Therefore, a deeper understanding of the disease is urgently needed in order to establish new diagnostic and therapeutic approaches. Exosomes, a kind of extracellular vesicles secreted by cells, can deliver various bioactive molecules, such as proteins, mRNA, mircoRNA, lipids, etc, and their potential value in the diagnosis, treatment and prognosis of lung cancer has been supported by a large number of literatures. In this review, we reviewed the development, early diagnosis, treatment and prognosis of non-small cell lung cancer.

关键词: 外泌体; 非小细胞肺癌; 早期诊断; 治疗

Key words: Exosome; non-small cell lung cancer; early diagnosis; treatment

1. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin, 2017, 67(3): 177-193.
2. Yang Q, Diamond MP, Al-Hendy A. The emerging role of extracellular vesicle-derived miRNAs: implication in cancer progression and stem cell related diseases. J Clin Epigenet, 2016, 2(1): pii: 13.
3. Munson P, Shukla A. Exosomes: Potential in Cancer Diagnosis and Therapy. Medicines (Basel), 2015, 2(4): 310-327.
4. Johnstone RM, Adam M, Hammond JR, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem, 1987, 262(19): 9412-9420.
5. Taverna S, Giallombardo M, Gil-Bazo I, et al. Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. Oncotarget, 2016, 7(19): 28748-28760.
6. Ventimiglia LN, Alonso MA. Biogenesis and function of T cell-derived exosomes. Front Cell Dev Biol, 2016, 4: 84.
7. Van Niel G, Mallegol J, Bevilacqua C, et al. Intestinal epithelial exosomes carry MHC class II/peptides able to inform the immune system in mice. Gut, 2003, 52(12): 1690-1697.
8. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol, 2002, 2(8): 569-579.
9. Mathivanan S, Simpson RJ. ExoCarta: A compendium of exosomal proteins and RNA. Proteomics, 2009, 9(21): 4997-5000.
10. Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol, 2007, 9(6): 654-659.
11. Frediani JN, Fabbri M. Essential role of miRNAs in orchestrating the biology of the tumor microenvironment. Mol Cancer, 2016, 15(1): 42.
12. Cui H, Seubert B, Stahl E, et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene, 2015, 34(28): 3640-3650.
13. Hsu YL, Hung JY, Chang WA, et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene, 2017, 36(34): 4929-4942.
14. Rahman MA, Barger JF, Lovat F, et al. Lung cancer exosomes as drivers of epithelial mesenchymal transition. Oncotarget, 2016, 7(34): 54852-54866.
15. Berchem G, Noman MZ, Bosseler M, et al. Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer. Oncoimmunology, 2015, 5(4): e1062968.
16. 万双双, 蔡志坚. 外泌体在肿瘤生物治疗中的研究进展. 中国肿瘤生物治疗杂志, 2016, 23(4): 571-574.
17. Wang Y, Yi J, Chen X, et al. The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-β and IL-10. Oncol Lett, 2016, 11(2): 1527-1530.
18. Cai Z, Yang F, Yu L, et al. Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol, 2012, 188(12): 5954-5961.
19. Li J, Yu J, Zhang H, et al. Exosomes-Derived MiR-302b Suppresses Lung Cancer Cell Proliferation and Migration via TGFβRII Inhibition. Cell Physiol Biochem, 2016, 38(5): 1715-1726.
20. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 2008, 18(10): 997-1006.
21. Rabinowits G, Gerçel-Taylor C, Day JM, et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer, 2009, 10(1): 42-46.
22. Cazzoli R, Buttitta F, Di Nicola M, et al. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol, 2013, 8(9): 1156-1162.
23. Huang SH, Li Y, Zhang J, et al. Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells. Cancer Invest, 2013, 31(5): 330-335.
24. Park JO, Choi DY, Choi DS, et al. Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. Proteomics, 2013, 13(14): 2125-2134.
25. Sandfeld-Paulsen B, Jakobsen KR, Bæk R, et al. Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer. J Thorac Oncol, 2016, 11(10): 1701-1710.
26. Clark DJ, Fondrie WE, Yang A, et al. Triple SILAC quantitative proteomic analysis reveals differential abundance of cell signaling proteins between normal and lung cancer-derived exosomes. J Proteomics, 2016, 133: 161-169.
27. Li W, Hu Y, Jiang T, et al. Rab27A regulates exosome secretion from lung adenocarcinoma cells A549: involvement of EPI64. APMIS, 2014, 122(11): 1080-1087.
28. Romagnoli GG, Zelante BB, Toniolo PA, et al. Dendritic Cell-Derived Exosomes may be a Tool for Cancer Immunotherapy by Converting Tumor Cells into Immunogenic Targets. Front Immunol, 2015, 5: 692.
29. Besse B, Charrier M, Lapierre V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology, 2015, 5(4): e1071008.
30. Srivastava A, Amreddy N, Babu A, et al. Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep, 2016, 6: 38541.
31. Kim MS, Haney MJ, Zhao Y, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine, 2016, 12(3): 655-664.
32. Aqil F, Kausar H, Agrawal AK, et al. Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp Mol Pathol, 2016, 101(1): 12-21.
33. Dejima H, Iinuma H, Kanaoka R, et al. Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncol Lett, 2017, 13(3): 1256-1263.
34. Yuwen DL, Sheng BB, Liu J, et al. MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Eur Rev Med Pharmacol Sci, 2017, 21(11): 2650-2658.
35. Sandfeld-Paulsen B, Aggerholm-Pedersen N, Bæk R, et al. Exosomal proteins as prognostic biomarkers in non-small cell lung cancer. Mol Oncol, 2016, 10(10): 1595-1602.
36. Silva J, García V, Zaballos Á, et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J, 2011, 37(3): 617-623.